The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 07, 2020

Filed:

Sep. 14, 2017
Applicant:

Dimerix Bioscience Pty Ltd, Nedlands, Western Australia, AU;

Inventors:

Kevin D. G. Pfleger, Nedlands, AU;

Elizabeth McCall, Dalkeith, AU;

James Williams, Kensington, AU;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/537 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/28 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/80 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4184 (2013.01); A61K 9/0019 (2013.01); A61K 9/2009 (2013.01); A61K 9/2054 (2013.01); A61K 31/28 (2013.01); A61K 31/4178 (2013.01); A61K 31/537 (2013.01); A61K 31/80 (2013.01); A61K 45/06 (2013.01);
Abstract

The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.


Find Patent Forward Citations

Loading…